Barkerville Gold Intersects 12.30 G/T AU Over 7.50 Metres at Island Mountain

Barkerville Gold Mines Ltd. {TSX.V: BGM} announced additional results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company's flagship Cariboo Gold Project.

Wide Veining Corridors were intersected at Shaft and Mosquito Creek Zones.

BGM Intersects 12.30 G/T AU Over 7.50 Metres at Island Mountain
March 21st, 2017

Wide Veining Corridors Intersected at Shaft and Mosquito Creek Zones

TORONTO, ON – March 21, 2017 – **Barkerville Gold Mines Ltd. {TSX.V: BGM}** is pleased to announce additional results from the ongoing 130,000 metre Phase II Island Mountain exploration drilling program at the Company's flagship Cariboo Gold Project.

The Company is currently exploring and delineating Island Mountain with seven drill rigs and has now relocated an eighth rig to the Valley Zone which occurs between Cow and Island Mountains. Detailed drilling results, a drill hole location plan map, vertical and long section are presented at the end of this release.

Drilling Highlights:

IM-17-036: 16.96 g/t Au over 5.15 metres
IM-17-037: 6.26 g/t Au over 16.20 metres
IM-17-038: 12.30 g/t Au over 7.50 metres
IM-17-040: 5.20 g/t Au over 19.90 metres
IM-17-041: 5.60 g/t Au over 8.95 metres
Note: Core lengths are reported as true widths cannot be accurately determined from the information available.

Mosquito Creek Zone

A thick corridor of auriferous veining has been intersected by drillhole IM-17-040 averaging 5.20 g/t Au over 19.90 metres located 100 metres northwest of the former Mosquito Creek Mine. This intersection occurs 20 metres directly up dip of previously reported drillhole IM-17-032 which intersected 12.19 g/t Au over 3.60 metres at a vertical depth of 50 metres below surface. This new mineralization remains open for expansion and drilling is presently testing the lateral and depth extensions of this newly discovered vein system.

Shaft Zone Continuity Established in New Vein Corridor

Demonstrating strong continuity on 60-100 metre drill spacings, a wide veining corridor was established by drillholes IM-17-037: 6.26 g/t Au over 16.20 metres, IM-17-038: 12.30 g/t Au over 7.50 metres and IM-17-041: 5.60 g/t Au over 8.95 metres. This new vein system has been traced from near surface down to 210 metres vertically below surface over a dip length of 170 metres.

At a vertical depth of 235 metres below surface in an untested portion of the Shaft Zone, drillhole IM-17-036 intersected a new occurrence of veining averaging 16.96 g/t Au over 5.15

metres and represents one of the deepest Phase II intersections of auriferous veining to date in this area. This new occurrence is open for expansion in all directions.

Chris Lodder, President and CEO comments, "*With the exploration teams geological model now proving solid, BGM's Island Mountain Drill program continues to identify new areas of significant, near surface mineralization. These multiple zones of mineralization are open at depth and along strike in both directions. Over the next few months drilling will concentrate on both infilling these new zones and stepping out along predicted geologic controls to find new ones".*

About the Phase II Program

The 130,000 metre 2017 Phase II exploratory and delineation drill program on Island Mountain is intended to determine the extent of the vein systems that were historically never explored, and is aimed at discovering new vein systems and sulphide replacement bodies that will ultimately inform a maiden resource. Seven drill rigs are currently operating on Island Mountain, with an eighth rig testing for additional mineralization below the former Aurum and Cariboo Gold Quartz Mines which have never been explored since mining operations ceased circa 1960.

Qualified Persons

Exploration activities at the Cariboo Gold Project are administered on site by the Company's Exploration Manager, Maggie Layman, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for

the Company and has prepared, validated and approved the technical and scientific content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company's secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by
the Company's Qualified Person, Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to ALS Geochemistry's analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 250 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 0.01 ppm and upper limit of 100 ppm. Samples with gold assays greater than 100 ppm are re-analysed using a 1,000g screen metallic fire assay. A selected number of samples are also analysed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-

MS).

For further information on Barkerville Gold Mines Ltd. please contact:

Chris Lodder
President & Chief Executive Officer
Suite 400-365 Bay Street
Toronto, Ontario, Canada

George Bickerstaff Elected to Inovio Pharma's Board of Directors

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced today the election of George Bickerstaff to its Board of Directors.

Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He has served Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric.

George Bickerstaff Elected to Inovio's Board of Directors

Former Novartis CFO brings finance, fundraising and M&A experience to Inovio

PLYMOUTH MEETING, Pa. – March 21, 2017 – **Inovio Pharmaceuticals, Inc. (NASDAQ: INO)** announced today the election of George Bickerstaff to its Board of Directors.

Mr. Bickerstaff is an internationally recognised expert in finance, healthcare and information technology. He has served Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M. Dillon & Co., an investment bank and financial advisory firm.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "*George Bickerstaff's finance, operations and international business experience will be an asset to Inovio as we advance our products to commercialization and enter collaborative arrangements with other companies. The addition of George to our Board helps ensure that Inovio will continue to benefit from a deep and wide range of experience.*"

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile.

With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

CONTACT:
Bernie Hertel
+1 858 410
bhertel@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative

therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Cartier Resources close flow through financing

Cartier Resources {TSX.V: ECR} confirm closure of their previously announced CAD $3.466 million flow through financing.

Agnico Eagle has maintained its approximate pro-rata 19.85% holding.

March 20, 2017 12:25 ET

Cartier Resources Announces Closing of C$3,477,600 Flow-Through Financing
VAL-D'OR, QUÉBEC–(Marketwired – March 20, 2017) –

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Cartier Resources Inc. (TSX.V:ECR) is pleased to announce the closing of a private placement (the "Offering") through Paradigm Capital Inc. (the "Agent"). Cartier issued 12,880,000 flow-through shares of the Company (the "Flow-Through Shares") at a price of C$0.27 per Flow-Through Share for total gross proceeds of C$3,477,600. The Offering included the full exercise of the Agent's overallotment option.

In connection with the Offering, the Agent, received a cash commission equal to 7% of the gross proceeds received by the company. In addition, broker warrants, equal to 7% of the number of Flow-Through Shares sold pursuant to the Offering (the "Broker Warrants") have been issued to the Agent. Each Broker Warrant shall entitle the holder thereof to acquire one

(1) common share at a price of $0.27 for a period of 24 months.
All of the securities issued under this offering are subject to a hold period of four months and one day in accordance with applicable Canadian securities laws.

Cartier is also pleased to announce that pursuant to the Investor Rights Agreement between Cartier and Agnico Eagles Mines Limited (“Agnico Eagle”), Agnico Eagle has maintained its approximate pro-rata 19.85% interest in Cartier after giving effect to the Offering.

The Company intends to use the gross proceeds of the Offering for “Canadian Exploration Expenses” (within the meaning of the Income Tax Act (Canada)) related to the Company’s Québec mining claims. The Company will agree to renounce such Canadian Exploration Expenses with an effective date of no later than December 31, 2017.

Cautionary Statements
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Statements: Certain disclosures in this release constitute forward-looking statements. In making the forward-looking statements in this release, the Company has applied certain factors and assumptions that are based on the Company’s current beliefs as well as assumptions made by and information currently available to the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause

future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors include, among others, those matters identified in its continuous disclosure filings, including its most recently filed MD&A. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

“Analysing the Diamond Miners” presentation in London

The Association of Mining Analysts are hosting a presentation with mining analyst of 2016 Des Kilalea, and Richard Hatch from RBC Capital Markets, who will walk us through the way they analyse diamond miners.

This is a rare opportunity to listen and learn from two experts in the field, and we have been allowed a limited number of tickets for this event, which takes place on 30th March at 18.00. For a free ticket please email **andrew@city-invstors-circle.com**

Thursday 30th March 2017

I am pleased to inform you that the Association of Mining Analysts are running a presentation by Mining Analyst of the year 2016 Des Kilalea, and Richard Hatch from RBC Capital Markets, who will walk us through the way they analyse diamond miners.

This is a rare opportunity to listen and learn from two experts in the field, and we have been allowed a limited number of tickets for this event, which is 80% full already.

This presentation is free to attend.

Program:
17.30 Guests arrive – networking
18.00 Presentation

19.00 Complimentary drinks and networking

Dress Code – Business / smart casual

Advance registration required.

If you wish to attend this event, please respond as soon as possible, once the allocation is full we will close the list.

If you wish to attend, you can register by emailing – andrew@city-investors-circle.com

---

Bitcoin price declining after ETF refusal and developer split

Bitcoin BTC – The price has fallen back considerably from the recent highs, partly because of the ETF request being declined by the SEC, and party due to a split amongst the development community over the size limit for a block of transactions..

Bitcoin BTC has fallen back from the recent intraday highs of $1,250, and now stands at $1,038. After such a surge a correction was half expected, but the principal reasons for this decline are twofold:

The request to the SEC to allow a Bitcoin ETF was declined. This would have made investing in Bitcoin very easy for people that perhaps didn't want an electronic "wallet", and would certainly have attracted fresh funds into Bitcoin, and driven the price higher.

Amongst the development community there is a serious rift about the size of a 'block' or batch of transactions which is limited to 1 megabyte size. Some developers want this increased, whilst others don't, hence the increasingly acrimonious split in the Bitcoin community.

All eyes will be on Bitcoin tomorrow to see if it holds the $1,000 level,or breaches it. The next good support level is $980.

Cascadero Copper – Updated presentation

Cascadero Copper {TSX.V: CCD} have updated their corporate presentation to reflect progress since the previous release.

To read the full article please CLICK HERE

Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} reported financial results for the fourth quarter and year ended December 31, 2016.

Total revenue was $8.5 million and $35.4 million for the quarter and year ended December 31, 2016, as compared to $5.9 million and $40.6 million for the same periods in 2015.

Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results

PLYMOUTH MEETING, PA – March 15, 2017 – **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** reported financial results for the fourth quarter and year ended December 31, 2016.

Total revenue was $8.5 million and $35.4 million for the quarter and year ended December 31, 2016, as compared to $5.9 million and $40.6 million for the same periods in 2015.

Total operating expenses for the quarter and year and ended December 31, 2016, were $30.9 million and $111.6 million as compared to $20.5 million and $74.9 million for the same periods in 2015.

The net loss attributable to common stockholders for the quarter and year ended December 31, 2016, was $26.2 million, or $0.35 per share, and $73.7 million, or $1.01 per share, compared to a net loss attributable to common stockholders of

$18.0 million or $0.25 per share, and $29.2 million, or $0.43 per share, for the quarter and year ended December 31, 2015.

Dr. J. Joseph Kim, President and CEO, said: "*In 2016 Inovio made significant progress on all three focuses of its Vision 2020 plan, which are HPV-related precancer, immuno-oncology, and infectious diseases, with notable data, multiple trial completions, progressive clinical study preparations, and multiple valuable collaborations and funding agreements. In 2017 we expect to report immune response data from clinical studies in six different diseases; the initiation of our phase 3 study of cervical dysplasia and two immuno-oncology combination studies, one by MedImmune and one by Inovio; and additional business development steps. We look forward to a highly productive year in advancing our unique immunotherapy platform and products.*"

Revenue

The decrease in revenue for the year was primarily due to $15.0 million of revenue recognized in 2015 from the up-front payment received from our partnership agreement with MedImmune. Accounting recognition of the remainder of the $27.5 million upfront payment was deferred and will be triggered by future events.

Operating Expenses

Research and development expenses for the quarter and year ended December 31, 2016, were $23.9 million and $88.7 million as compared to $15.6 million and $57.8 million for the same periods in 2015. The increase was primarily related to increased investment in our product development programs –

notably the DARPA funded Ebola program and clinical trial preparations for the initiation of the VGX-3100 phase 3 study. General and administrative expenses for the quarter and year ended December 31, 2016, were $7.0 million and $23.9 million, compared to $4.9 million and $18.1 million for the quarter and year ended December 31, 2015. The increase was primarily related to employee non-cash stock-based compensation and employee headcount.

Capital Resources

As of December 31, 2016, cash and cash equivalents and short-term investments were $104.8 million compared with $163.0 million as of December 31, 2015. As of December 31, 2016, the company had 74.1 million shares outstanding and 82.0 million fully diluted.

During the year ended December 31, 2016, the Company sold 658,748 shares of common stock under its ATM common stock sales agreement for net proceeds of $6.3 million, with an average price of $9.75 per share.

Subsequent to year end Inovio announced a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialise VGX-3100 within Greater China. In this agreement, Inovio will receive a $3 million signing fee and a $12 million milestone upon lifting of the VGX-3100 phase 3 pre-initiation clinical hold by the FDA. ApolloBio will also invest in Inovio common stock subsequent to lifting of the clinical hold at a volume weighted average price encompassing a trading period prior to and following the lifting of the clinical hold. The aggregate investment, expected to be completed in the first half of 2017, will not exceed $35 million and may be a lower amount such that ApolloBio will not be the largest shareholder in Inovio. Further details are

provided under Corporate Update, HPV-Related Precancers below.

Inovio's balance sheet and statement of operations are provided below. Form 10-K providing the complete 2016 annual financial report can be found at: http://ir.inovio.com/secfilings.

Corporate Update

HPV-Related Precancers

In 2016 Inovio completed the scaling up of immunotherapy manufacturing to a commercial-scale facility as well as the commercial design and manufacturing process development for its new CELLECTRA® 5PSP electroporation delivery device. We submitted a regulatory package to the U.S. Food and Drug Administration (FDA) supporting our proposed initiation of our phase 3 clinical program for VGX-3100 for HPV-related high grade cervical dysplasia. Included in this package was an extensive submission regarding the new device. Prior to the initiation of this study the FDA placed this program on clinical hold and subsequently provided Inovio with comments and questions, including a request for certain stability data relating to the device's single-use disposable needle array. Inovio is generating the necessary data to prepare a comprehensive response. We aim to begin the phase 3 clinical program in the first half of 2017, subject to the FDA's review of our response and lifting of the clinical hold. This clinical hold does not affect other Inovio clinical programs.

Inovio is planning to launch a phase 2 clinical study in 2017 for another HPV-related disease, vulvar intraepithelial neoplasia.

Subsequent to year end Inovio announced it entered into a collaboration and license agreement providing ApolloBio Corporation with the exclusive right to develop and commercialise VGX-3100 within Greater China (China, Hong Kong, Macao, Taiwan). The agreement provides for potential inclusion

of the Republic of Korea three years following the effective date. Apart from financial terms discussed in Capital Resources above, ApolloBio will pay all clinical development costs within the licensed territory, up to $20 million based upon the achievement of certain regulatory milestones in the US, China and Korea, and double digit royalties on net sales of VGX-3100. The agreements are subject to People's Republic of China (PRC) corporate and regulatory approvals, and payments are subject to PRC currency approvals. This collaboration encompasses treatment and/or prevention of pre-cancerous HPV infections and HPV-driven dysplasias, and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants.

Immuno-Oncology

In the fourth quarter we reported interim data showing that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood in four of five subjects with HPV-related head and neck cancer who also showed increased T cell activation in resected tumor tissue samples. This data suggests the potential of Inovio's DNA immunotherapies to turn tumors from cold to hot – by dramatically increasing the presence of killer T cells in the tumor, this technology represents an ideal approach to enhance the capabilities of checkpoint inhibitors. Inovio expects its partner, MedImmune, which licensed INO-3112 in 2015, to initiate a phase 1/2 immuno-oncology combination clinical study including INO-3112 in 1H 2017.

Subsequent to year end we reported data indicating that our SynCon® WT1 cancer antigen was capable of breaking immune tolerance – a major challenge to researchers striving to develop potent cancer therapies – and induced neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. The results were published in Molecular Therapy in an article entitled, "A novel DNA vaccine platform enhances neo-antigen-like T-cell responses against WT1 to break tolerance

and induce anti-tumor immunity.” Inovio previously reported such results for its SynCon hTERT and PSMA cancer antigens. All three antigens are encoded in INO-5401, Inovio’s new universal cancer vaccine. Inovio intends to advance INO-5401 into a phase 1/2 study in combination with a checkpoint inhibitor in 1H 2017.

Completed enrollment of 62 subjects in the phase 1 study of our INO-5150 prostate cancer immunotherapy. We expect to report interim immune response and safety data in 2017.

Infectious Diseases

Subsequent to year end Inovio completed enrollment of its phase 1 study of its hepatitis B DNA immunotherapy (INO-1800). Inovio is independently advancing this program following Roche’s notice in 2016 that it will discontinue its INO-1800 collaboration with Inovio. All of Roche’s rights to INO-1800 have been returned. Inovio expects to report preliminary immune response data in 2H 2017. The study has completed interim safety reviews with a favorable safety profile to date.

Subsequent to year end we reported that in our emerging epidemic infectious disease program our fully enrolled 75-subject phase 1 study of our MERS DNA vaccine GLS-5300 generated high levels of binding antibodies (ELISA) in 92% (57 of 62) of evaluated subjects after three vaccinations (84% after two doses; 44% after one dose). Similarly, in our fully enrolled 40-subject phase 1 Zika study of GLS-5700, high levels of binding antibodies were measured (ELISA) in 100% (39 of 39) of evaluated subjects after three vaccinations; 82% (32 of 39) after two doses; 40% (16 of 40) after one dose. Both vaccines were well tolerated with no significant safety concerns to date. **Both programs are being advanced through collaborations between Inovio and GeneOne Life Science Inc. (KSE: 011000).**

We announced a collaboration and funding through our collaborator, GeneOne Life Science, with the International Vaccine Institute (IVI), which will provide technical, laboratory and financial support for GLS-5300 (MERS) clinical trials in Korea. This program is part of a grant provided to IVI by the Samsung Foundation.

Inovio and GeneOne initiated a phase 1 Zika DNA vaccine trial in Puerto Rico to test for safety, immune responses and initial evidence of efficacy. The placebo-controlled double-blind trial will assess differences in Zika infection rates in 160 healthy participants given either placebo or vaccine as part of an exploratory endpoint.

We expanded our phase 1 Ebola vaccine trial by fully enrolling an additional 125 subjects in a second stage after generating positive initial safety and immune response data in the first set of 75 healthy volunteers. The study will assess immune response characteristics generated with fewer intradermal administrations, lower doses, and with and without Inovio's DNA-based IL-12 immune activator.

In 2016 we partnered with the National Cancer Institute and Mayo Clinic to initiate a phase 1 trial of our immunotherapy for hepatitis C (INO-8000). The dose escalation study will enroll patients in the early stages of chronic HCV infection to determine the therapy's ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability.

Completed enrollment of 94 subjects in the phase 1 study of our PENNVAX®-GP HIV immunotherapy. After completing extensive immunogenicity analyses, we expect to report data in 2H 2017.

Other Developments

Signed collaborative research agreements with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy applications and products for cancers and

infectious diseases developed by David B. Weiner, Ph.D., board member and chairman of the scientific advisory board, and his Wistar laboratory. Inovio will have the exclusive right to in-license new intellectual property developed in this collaboration.

Inovio announced the award of a $6.1 million sub-grant through The Wistar Institute to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection. This program (a total of $8.8 million) is funded by the Bill & Melinda Gates Foundation.

Inovio's DNA-based monoclonal antibody technology will be used to develop new immunotherapy approaches to treat HIV. This work will be funded by a $23 million grant, called BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, from the National Institutes of Health to The Wistar Institute, an Inovio collaborator, and more than 30 of the nation's leading HIV investigators.

Inovio incorporated a 100%-owned subsidiary, GENEOS Therapeutics, Inc., to develop and commercialize neo-antigen based personalized cancer therapies. GENEOS will exclusively focus on leveraging Inovio's potent DNA immunotherapy technology platform to advance the emerging field of patient-specific neo-antigen therapies. GENEOS plans to independently raise capital and build a team to execute this complementary business model. Inovio will continue its focus on advancing its universal antigen-specific cancer immunotherapy portfolio.

Received $500,000 grant from the U.S. Army's Small Business Innovation Research program to advance Inovio's next generation delivery device capable of administering vaccines via skin-surface, needle-free electroporation.Inovio completed the acquisition of all of Bioject Medical Technologies Inc.'s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, for $5.5 million in cash and stock. Our goal is to design an integrated needle-free immunotherapy delivery and electroporation device.

Licensed a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences, an animal health company

headquartered in South Korea. Plumbline will fund all development activities for this FMD vaccine and pay Inovio milestone payments as well as royalties on potential product sales.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. The company is advancing a growing clinical and preclinical stage product pipeline. Partners and collaborators include MedImmune, the Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute and U.S. Military HIV Research Program.

For more information, please visit **www.inovio.com**

CONTACT:
Investors: Bernie Hertel

+1 858-410-3101

bhertel@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein

as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, including our ability to obtain a release of the clinical hold from the FDA for the proposed phase 3 clinical program for VGX-3100, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2016 and other regulatory filings from time to time. There can be no

assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Kootenay Reports Follow Up Metallurgical Leach Testing Underway on Bulk Samples from La Cigarra

Kootenay Silver Inc. {TSX.V: KTN} reported additional leach testing of oxide and sulphide silver mineralisation (the "Phase II Program") has begun on bulk samples from the Company's La Cigarra silver deposit in Chihuahua State, Mexico, applying the proprietary SILVOX Technologies Inc. process.

Kootenay Reports Follow Up Metallurgical Leach Testing Underway on Bulk Samples from La Cigarra Silver Resource

VANCOUVER, March 15, 2017 /CNW/ – **Kootenay Silver Inc. {TSX.V: KTN}** is pleased to report additional leach testing of oxide and sulphide silver mineralisation (the "Phase II Program") has begun on bulk samples from the Company's La Cigarra silver deposit in Chihuahua State, Mexico, applying the proprietary SILVOX Technologies Inc. ("SILVOX") process.

The purpose of the Phase II Program is to determine if silver mineralisation at La Cigarra is amenable to low cost heap leach processing using the SILVOX process, which could have a positive impact on potential capital requirements and operating costs. Previous metallurgical work was focused on silver recovery through production of a concentrate via conventional floatation. This work was very positive achieving recoveries up to 88% silver producing a high grade lead-silver concentrate that graded 34% lead and 23,000 gpt silver for every tonne of concentrate (see Northair Silver News Release dated June 29, 2015).

The Phase II Program was initiated based on positive results from preliminary metallurgical testing of the oxide mineralisation hosted within the La Cigarra deposit that showed a significant improvement in silver recoveries when using standard leaching with the SILVOX process, versus industry standard leaching without the SILVOX process (See Kootenay News Release dated January 2, 2017).

Phase II testing will involve bottle roll testing ("BR testing") on different crush sizes of ¼ and ¾ inch for oxide material and initial evaluation on ¼ inch for sulphide material, which was not previously tested. Metallurgical

testing will involve applying industry standard (“standard”) leach testing in addition to utilizing the SILVOX process to establish differences in recoveries and optimisation.

The metallurgical test work is part of a larger comprehensive approach to the La Cigarra property aimed at maximising the project’s near and long-term economic viability through resource expansion and optimization of the existing silver deposit.

Sampling and QA/QC

All technical information for the La Cigarra exploration program is obtained and reported under a formal quality assurance and quality control (“QA/QC”) program. Samples are taken under the direction of qualified geologists and stored in sealed bags. Samples are delivered by the Company via courier to ALS Minerals (“ALS”) in Chihuahua. The samples are dried, crushed and pulverized with the pulps being sent airfreight for analysis by ALS in Vancouver B.C. Systematic assaying of standards is performed for precision and accuracy. Analysis for silver, zinc, lead and copper and related trace elements was done by ICP four acid digestion, with gold analysis by 30 gram fire assay with an AA finish.

Qualified Persons

The Kootenay technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 (Standards of Disclosure for Mineral Projects) and reviewed on behalf Kootenay by James McDonald, P.Geo, President, CEO & Director for Kootenay, a Qualified Person.

WesternZagros release Q4 2016 and Year End results

WesternZagros Resources Ltd. (TSX.V: WZR) (“WesternZagros” or “the Company”) announced its operating and financial results for the fourth quarter and year ended December 31, 2016.

To read the full article please CLICK HERE

Or paste this code into a browser

http://westernzagros.mwnewsroom.com/press-releases/westernzagros-announces-2016-fourth-quarter-and-ye-tsx-venture-

wzr-20170315108885300 1

Neometals confirm 2nd shipment of lithium concentrate from Mt. Marion.

Neometals Ltd (ASX:NMT), Mineral Resources Ltd. {ASX:MIN} and Ganfeng Lithium Co. Ltd advised that the second shipment of lithium concentrates from the Mt Marion Lithium Project ('Mt Marion') has departed from the Port of Kwinana.

The 16,662 tonne shipment contained concentrate at +6% and +4% Li2O.

Neometals

SECOND SHIPMENT OF LITHIUM CONCENTRATE FROM MT MARION

Neometals Ltd (ASX:NMT), Mineral Resources Ltd. {ASX:MIN} and Ganfeng Lithium Co. Ltd wish to advise that the second shipment of lithium concentrates from the Mt Marion Lithium Project ('Mt Marion') has departed from the Port of Kwinana.

The 16,662 tonne shipment containing concentrate at +6% and +4% Li2O was loaded onto the MV Babuza Wisdom which departed Kwinana on Tuesday 14th March enroute to Ganfeng's receiving facility at Zhenjiang Port, China.

This shipment follows the maiden shipment of 15,000 tonnes which departed on 6 th February 2017, while the next shipment of approximately 18,000 tonnes of concentrate is expected to be loaded early April, on the MV Pacific Venus, which is returning to port after sailing with the maiden cargo. ENDS

For further information, please contact:

Chris Reed Managing Director Neometals Ltd

+61 8 9322 1182

info@neometals.com.au

Avalon closes preferred share placing

Avalon Advanced Materials {TSX: AVL} announced that it has closed its previously announced preferred share financing with an entity managed by The Lind Partners, a New York based asset management firm, as described in the Company's news release dated 3rd March 2017.

March 10, 2017

Toronto, ON – **Avalon Advanced Materials {TSX: AVL}** is pleased to announce that it has closed its previously announced preferred share financing with an entity managed by The Lind Partners, a New York based asset management firm ("Lind"), as described in the Company's news release of March 3, 2017.

The financing involved the issuance of 500 Series A1 Preferred Shares on a private placement basis at a price of $5,000 per share for gross proceeds of $2,500,000. In addition, Lind received 6,900,000 common share purchase warrants exercisable until March 10, 2022 at a price of $0.23 per common share.

The proceeds will be used for ongoing market development work, metallurgical studies and preliminary engineering work on the Separation Rapids Lithium Project and for general working capital purposes. The work at Separation Rapids will include a 2,000 metre diamond drilling program scheduled to begin during the week of March 20. This program will test projected extensions of the presently defined petalite resource, known to be enriched in lithium mica (lepidolite) mineralisation.

This news release is not an offer of securities for sale in the United States. The securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and may not be offered or sold in the United States or to US persons (as defined in Regulation S under the US Securities Act) absent registration or an applicable exemption from registration. All currency reported in this release is in Canadian dollars.

Bitcoin ETF denied- Causes large fall in Bitcoin value on the day

Bitcoin {BTC} requested an ETF be established to allow market participants to be able to trade Bitcoin in the market rather than in an electronic wallet, but this has been refused, and that refusal resulted in a 15% drop in value, in a sharp reversal.

Bitcoin suffered a sharp reverse upon hearing the BTC ETF had been denied, but the price is already recovering as the lower price brought out bargain hunters.

The assumption was that an approved ETF would open the floodgates to both Wall Street and regular investors who want a stake in the digital currency but didn’t feel comfortable purchasing it on their own. This influx of new investors would then drive up the price of Bitcoin. even further.

Instead, the rejection of the proposal had a devastating

opposite effect. The value of the digital currency dropped from $1,295 to as low as $1,000, and stabilised at $1,120, for a 15% drop on the day.

The reason the SEC gave for the rejection of Bitcoin is the very reason it has become so popular, it is an extremely unregulated currency, and doesn't comply with SEC standards.

Are the authorities running scared of crypto currencies such as BTC?

Minera IRL -COFIDE revokes their mandate for Ollachea debt

Minera IRL Limited {CSE: MIRL} announces that Corporacion Financiera de Desarrollo of Peru **("COFIDE")** has advised that it has revoked the mandate to exclusively structure the senior debt to a maximum of US$240 million for the development of the Ollachea gold project in Puno, Peru.

COFIDE has changed its strategy to focus on financing small and medium industry.

The Peruvian Government announced on March 9, 2017 an Economic Impulse Plan that
will prioritize the credit for the Mypes through COFIDE, among other measures to boost
the Peruvian economy.

The Company is assessing its options to finance the development of the Ollachea Project
and has been developing an optimized plan to enhance shareholder value.

Diego Benavides, CEO and Director, of Minera IRL said, "*We are confident of being able to obtain the necessary investment to develop Ollachea on shareholder-friendly terms. We anticipate being able to bring news of further developments to the market in the near future.*"

FOR FURTHER INFORMATION, PLEASE CONTACT:
Minera IRL Limited
Diego Benavides Norlander
Chief Executive Officer +51 1 418 1230
Minera IRL Limited
Carlos Ruiz de Castilla +1 778 387 5434
Chief Financial Officer

No stock exchange, securities commission or other regulatory authority has approved or
disapproved the information contained in this news release.
Ordnance House ◦ 31 Pier Road: St Helier, Jersey ◦ JE4 8PW ◦ Channel Islands
minera@irl.com.pe

www.minera – irl.com

Cautionary Statement on Forward-Looking Information
Certain information in this news release, including information about the Company's financial or operating performance, information about the legislative regime to which the Company is subject, and other statements expressing management's expectations or estimates of future events, performance and exploration and development programs or plans constitute "forward-looking statements". Forward-looking statements in this press release include our plans for establishment of updated resource estimates and the expected timing to accomplish each of them. Forward-looking statements are, necessarily, based upon a number of estimates and assumptions. While considered by management to be reasonable in the context in which they are made, forward-looking statements
are inherently subject to political, legal, regulatory, business and economic risks and competitive uncertainties and contingencies. The Company cautions readers that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Minera IRL's actual financial results, legislative environment, future performance and results of exploration and development programs and plans to be materially different than those expected or estimated future results, performance or achievements and that forward-looking statements are not guarantees of future performance, results or achievements.
Minera IRL assumes no obligation, except as may be required by

law, to update or revise them to reflect new events or circumstances. Risks, uncertainties and contingencies and other factors that might cause actual performance to differ from forward-looking statements include, but are not limited to, any failure to obtain or complete project financing for the Ollachea Gold Project (including the Senior Debt Facility), availability of labour and equipment and financial resources, delays in development or in receiving reports on our development, changes in the price of precious metals and commodities, changes in the relative exchange rates of the US dollar against the Peruvian nuevo sol, interest rates, legislative, political, social or economic developments both within the countries in which the Company operates and in general, contests over title to property, the speculative nature of mineral exploration and development, operating or technical difficulties in
connection with the Company's development or exploration programs, increasing costs as a result of inflation or scarcity of human resources and input materials or equipment. Known and unknown risks inherent in the mining business include potential uncertainties related to the title of mineral claims, the accuracy of mineral reserve and resource estimates, metallurgical recoveries, capital and operating costs and the future demand for minerals. For additional information, please consult the Company's most recently filed MD&A and Annual Information Form.

Cascadero Copper – Drill permit issued, program

scheduled to start.

Cascadero Copper {TSX.V: CCD} Announced they have received notice that work can start on the Taron cesium showing.

The contractor will mobilise the required equipment to rehabilitate the access roads to the property to the drill hole collar locations. The camp for 18 workers should be on site within 7 days and the drill is expected to be on site February 26.

Cascadero Copper : DRILL PERMIT ISSUED – PROGRAM SCHEDULED TO START

The Company has received notice that work can start on the Taron cesium showing. The advance payment to the drill Contractor is in process and the Contractor will mobilise the required equipment to rehabilitate the access roads to the property to the drill hole collar locations. The camp for 18 workers should be on site within 7 days and the drill is expected to be on site February 26.

The Company is planning to drill 29 vertical HQ3 core holes to a depth of 75 metres for a total of 2,175 metres in a grid style pattern that will test an area of about 1.30 square kilometres in the southwest portion of the property. This is an area that has three previous drill holes (2009) and several hundred metres of hand and excavator trenches (2005 to 2007).

Additionally, the area has variable outcrops that all assayed cesium.

The Program is expected to take 50 days to complete. The Company has retained GeoSim Services Inc who will act as the Qualified Person (QP) for the program.

About Cesium

Cesium (chemical symbol Cs) is a rare metal best known for its extreme chemical reactivity. Cesium hydroxide forms the start point of myriad end uses, including Cesium Formate (CsCHO), the industries premium drilling and completion fluid. Cesium Formate is an environmentally benign solution with a high-density and low-viscosity used to control formation pressures and temperatures in drilling of deep oil wells (HPHT).

As a dense medium, cesium formate is used to separate DNA and in metallurgical testing and is also well known for artificially produced radioactive isotopes used to treat various types of cancer. Cesium compounds and chemicals are used in photo-emissive devices, experimental magneto-hydrodynamic electricity generation, atomic clocks for telecommunications and GPS navigation systems, catalysts in plastic manufacturing, specialty glasses, ion propulsion rocket motors, high-density alkaline batteries, coatings for solar cells, and petroleum refining. Research continues to generate new applications for cesium compounds.

Bill McWilliam

CEO

Cascadero Copper Corporation

Strongbow director buys in the market again

StrongBow Exploration Inc. {TSE: SBW} Director David Grenville Thomas purchased 114,500 shares of the company's stock in a transaction dated Wednesday, March 1st. The stock was purchased at an average cost of C$0.15 per share, with a total value of C$17,175.00.

David Grenville Thomas also recently made the following trade(s):

- On Tuesday, February 28th, David Grenville Thomas purchased 34,500 shares of StrongBow Exploration stock. The stock was purchased at an average cost of C$0.15 per share, with a total value of C$5,175.00.
- On Tuesday, February 21st, David Grenville Thomas purchased 100,000 shares of StrongBow Exploration stock. The stock was purchased at an average cost of C$0.15 per share, with a total value of C$15,000.00.

PDAC – Day 3

The PDAC mining conference in Toronto entered its third day today, amid some unseasonal slightly warmer weather and rain showers.

Less attendees today,maybe as the relentless post conference partying takes it's toll?

As is usual on he third day of this three and a half day marathon, the floor was much quieter,not many investors in the aisles,and some mutterings of discontent from the booths about "no investors, all trade people here", which of course is largely correct.

To avoid the packed flight home tomorrow,and an extra £260 fare!, i'm writing this from the airport prior to boarding my flight home

The Wednesday half day is always a non event so giving it a miss for once.

PDAC – Day 2

The PDAC mining conference in Toronto – Day 2 was far busier then the first day for a time from mid morning to mid afternoon, when the attraction of free hospitality undoubtedly took over, and there were many to choose from last night.

Monday is normally the busiest day in my eexperience, when Bay St.professionals enter the fray alongside those investors able to attend on a working day.

The new “hot” metal is cobalt, and I can imagine there will be a rush of re-namings to take advantage of the sudden interest in this supply restricted metal essential for batteries.

There are plenty of people trying to talk copper up, as some projects don;t work at the current low price, but sadly yesterday copper broke a key technical indicator to the downside!

Some booths are vry busy other areas seem quiet and holders complaining of the lack of footfall in their corridors, which is a tricky problem as the periphery is always quiet, they need to put some coffee areas there to draw in people to those areas.

The only AIM listed companies I have seen are **Condor Gold** and **Conroy Gold.**

The weather is above freezing today which is welcome, but the downside it it's raining!

PDAC – Day 1

PDAC, Toronto Canada. Day one of the four day mining fest that is the Prospectors and developers Conference, the world's largest mining show, enjoyed a healthy attendance, and, dare I say it, a return to exuberance!

I have been attending the PDAC for 10 years, so I have a good feel for the mood of the show.

After a few sombre years, I detect a feeling of genuine optimism and exuberance this year, a return of the Vancouver stock promoter even, noticeably absent for the last two years.

Amongst the people and CEO's I spoke to yesterday, the first day of the show, there is clearly a feeling that the worst is behind the mining sector now, and that things are moving positively again. I heard the in recent times rarely used phrase "10 bagger" used frequently when describing companies yesterday, and there is definitely a positive feel that has

been missing for some time.

I find more companies want to talk about engaging and connecting with European investors than in previous years, and that should manifest itself into more corporate visits and roadshows in the months ahead, as companies that have inactive in promoting their story emerge to update investors.

Another trend I noticed was less companies were looking to a roadshow tour to raise money, rather looking to come to create interest in their story , and update existing investors. A year ago this was entirely different, with nearly all companies only interested in raising money.

I also note that the show seems to have a similar number of booths to last year, which is surprising given the lift in the sector, I expected more exhibitors. The core shack, traditionally on the upper floor has been moves to the Investors Exchange area, to fill that end of the room.

This has allowed an expanded coffee area on the mezzanine level, which seems poorly thought out to me. Last year the seated area was in the exchange, where many people with tired feet could rest for a few minutes, but now you have to exit the exchange and go up a floor, which makes no sense at all.

GoldMining Inc selected for the TSX Venture 50

GoldMining Inc. (formerly Brazil Resources Inc.) {TSX-V: GOLD} announced it has been named to the 2017 TSX Venture 50, an annual ranking of top-performing companies on the TSX Venture Exchange (the “TSX-V”) over the last year. The Company was ranked second overall in the mining sector.

GoldMining INC included in the TSX Venture 50

Each year, the TSX Venture 50 ranking showcases listed companies that have shown notable results in key measures of market performance. The companies included in the 2017 TSX

Venture 50 were selected based on three equally weighted criteria: market capitalisation growth, share price appreciation and trading volume.

Amir Adnani, Chairman, stated: *"We are pleased to report that GoldMining Inc. placed in the top two mining companies selected for the 2017 TSX Venture 50. As announced earlier this month, the Company was also among the top four companies included in the 2017 OTCQX® Best 50, a ranking of top-performing equities traded on the US OTCQX market in 2016. These recognitions serve to validate the Company's strategic execution in 2016. We anticipate extending that same strategy into 2017 by targeting and acquiring additional gold projects of merit, where we see potential for substantial resource growth. With $20 million in cash and strong institutional backing, we will strive to earn the same results over the year ahead."*

About GoldMining Inc.

GoldMining is a public company with a focus on the acquisition, exploration and development of projects in Brazil, Colombia, the United States and Canada. The Company is advancing its São Jorge and Cachoeira Gold Projects in Brazil, Titiribi Gold-Copper Project in Colombia, Whistler Gold-Copper Project in Alaska and its Rea Uranium Project in the western Athabasca Basin in Canada.

For additional information, please contact:

GoldMining Inc.

Amir Adnani, Chairman

Patrick Obara, Chief Financial Officer

Telephone: +1 855 630 1001

The curse of the PDAC? – the conference starts tomorrow

The PDAC mining conference starts tomorrow in Toronto, Canada.

Over the years the event has caused the price of stocks falling after the event to be called “the curse of the PDAC”, as so many prices fall after the show has closed its doors!

The burning question has to be, will the “curse of the PDAC” return to haunt companies after the show this year?

In previous years share prices have dipped after the show, and people have often asked why, given the publicity generated by the show and the connections made with institutions and investors throughout the show.

I think the answer is simply that companies often release news before the show,and the share price is hyped up by promoters

leading up to the news, which means the top is already in ***before*** the show!

So. once the show is over, and all buyers are already in, the price pulls bqck as there is no new interest to buy the sells going into the market.

So the curse of the PDAC may well live up to its name this year, as we have seen some strong rises in stocks that have released news recently, we shall see.